News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Post-Approval (World)
Gedeon Richter (RIG2.F) Release: Full Results Of PEARL IV Study Presented At The European Society Of Gynaecological Endoscopy (ESGE) Congress Confirms The Efficacy Of Ulipristal Acetate 5 Mg For The Long Term Management Of Uterine Fibroids 10/9/2015
Boehringer Ingelheim Release: New Data Demonstrate Sustained Long-Term Efficacy Of OFEV* On Slowing Disease Progression And Safety In Patients With IPF 9/29/2015
MerLion Pharmaceuticals GmbH’s Finafloxacin Shown To Be More Efficacious Than Ciprofloxacin In The Treatment Of Complicated Urinary Tract Infections 9/21/2015
ERS 2015: Landmark Year For Boehringer Ingelheim’s Respiratory Portfolio - New Data For COPD, IPF And Asthma Treatments 9/21/2015
AmpliPhi Biosciences Corporation (APHB) Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model 9/21/2015
PharmaMar Showcases New Data For YONDELIS And PM1183 In Soft Tissue Sarcoma And Solid Tumors At ECCO 2015 9/14/2015
GlaxoSmithKline (GSK), Theravance (THRX)'s Breo Fails to Extend Lives in Ambitious Study 9/10/2015
GlaxoSmithKline (GSK) And Theravance (THRX) Announce Results From The SUMMIT COPD CV Survival Study 9/9/2015
Regeneron (REGN) And Sanofi (SNY) Announce New Positive Praluent (alirocumab) Phase 3 Data Presented At ESC Congress 2015 9/1/2015
Novartis AG (NVS) Reports Third Case of PML in Relapsing MS Patient Treated with Gilenya 8/19/2015
Veloxis Pharmaceuticals A/S (VELO) Envarsus XR Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis 8/17/2015
GlaxoSmithKline (GSK) Hopes Huge Trial Will Revive Flagging Lung Drug Biz 8/14/2015
Roche (RHHBY)'s Avastin Not Linked to Higher Risk of Blindness 8/14/2015
Zealand Pharma  (ZEAL.CO) Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial 6/9/2015
Zealand Pharma  (ZEAL.CO) Informs Of Updates Given By Sanofi (SAN.PA) On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes 6/9/2015
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SAN.PA) Has Informed Of Results From Getgoal Duo-2, Showing Advantages Of Lyxumia Versus Rapid-Acting Insulin As Add-On To Lantus For The Treatment Of Type 2 Diabete 6/8/2015
Boehringer Ingelheim Release: First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/13/2015
Teva (TEVA) Presents Data Comparing Early Treatment With COPAXONE 40 Mg/Ml To Delayed Start Treatment At 67th American Academy of Neurology Annual Meeting In Washington, D.C. 4/23/2015
AstraZeneca PLC (AZN)'s Diabetes Drug Onglyza May Increase Risk of Heart Failure, FDA Panel Reports 4/13/2015
Roche (RHHBY) Scientists Testing to See if Arthritis Blockbuster Will Work for Diabetes 4/10/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion On Application For Orphan Designation By The European Medicines Agency Agency For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 3/24/2015
Boehringer Ingelheim Release: Many Atrial Fibrillation Patients At High Risk Of Stroke Fail To Receive Guideline-Recommended Oral Anticoagulant Treatment 3/16/2015
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015
Celltrion Healthcare: Data Show The World’s First European Medicines Agency-Approved Biosimilar Monoclonal Antibody Remsima Could Reduce Cost Of Treating Crohn’s Disease By Up To €336 Million Over Five Years 2/20/2015
Novartis AG (NVS) May Already Have First True Anti-Aging Drug in Its Pipeline 2/19/2015
New Study Vindicates Efficacy of Roche (RHHBY)'s Blockbuster Drug Tamiflu 2/2/2015
DBV Technologies Announces Publication In The Journal Of Allergy And Clinical Immunology Of Data Demonstrating That Epicutaneous Immunotherapy May Influence The Natural History Of Allergy 1/12/2015
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Genentech (RHHBY) Provides Update On Phase 3 MARIANNE Study In People With Previously Untreated Advanced HER2-Positive Breast Cancer 12/19/2014
EXCLUSIVE: NHS Uses Ineffective IPF Therapy 12/5/2014
National Institute for Clinical Excellence (NICE) Requests More Info On Novartis AG (NVS)'s Xolair To Treat Chronic Hives 11/20/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents Positive Safety And Efficacy Data For QNASL® (Beclomethasone Dipropionate) Nasal Aerosol In Treating Children With Perennial Allergic Rhinitis 11/7/2014
Changing The Way We Combat Bacterial Infections: Dutch Biotech Micreos Launches First Bacteria-Killing Enzyme For Human Use Against MRSA 11/5/2014
AstraZeneca PLC (AZN)'s New Drug Olaparib May Also Work In Prostate Cancer 11/5/2014
Teva Pharmaceutical Industries Limited (TEVA) And Active Biotech AB (BTPC) Announce Expansion Of Laquinimod Clinical Development Program With New Trial In Primary Progressive Multiple Sclerosis And First Patient Screened In Huntington’s Disease Trial 11/4/2014
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia 11/3/2014
Boehringer Ingelheim GmbH Release: FDA Medicare Study In 134,000 Atrial Fibrillation Patients Confirms Positive Safety Profile And Effectiveness Of Pradaxa® In General Practice 11/3/2014
Roche (RHHBY), Merck & Co. (MRK) Extend Immunotherapy Battle To Breast Cancer 10/17/2014
Celgene International Sárl (CELG) Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis 10/10/2014
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis 10/10/2014
Celgene International Sárl (CELG) To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress 10/7/2014
Daiichi Sankyo, Inc. (4568.t) Receives Approval For Additional Indications Of LIXIANA® (Edoxaban) In Japan 9/26/2014
Regeneron Pharmaceuticals, Inc. (REGN) Announces EYLEA® (aflibercept) Injection Approved For The Treatment Of Patients With Myopic Choroidal Neovascularization (CNV) In Japan 9/22/2014
Janssen-Cilag International NV (JNJ) Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes 9/17/2014
Study Shows Novo Nordisk A/S (NVO)'s New Diabetes Drug Tresiba Effective And Safe For Children 9/16/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents New Data Which Demonstrate Reduction Of Injection-Related Adverse Events With The Less Frequent Dosing Of Three-Times-A-Week COPAXONE® (Glatiramer Acetate Injection) 40 Mg Compared To Daily COPAXONE® 20 Mg 9/11/2014
Novartis AG (NVS): Rate Of Brain Shrinkage Faster In Multiple Schlerosis Patients 9/10/2014
Novaliq GmbH Announces Positive Results From Novatears® Observational Study In Mild To Moderate Evaporative Dry Eye Disease 9/10/2014
Amgen (AMGN), Servier Heart Drug Runs Into Safety Concerns In Major Clinical Study 9/4/2014
Vifor Pharma Release: CONFIRM-HF Study Demonstrates That Injectafer® (Ferinject®) Improves Exercise Capacity In Patients With Chronic Heart Failure 9/2/2014
Boehringer Ingelheim Corporation Release: European Society of Cardiology Congress 2014 Hot Line Session: Favourable Effect Of Pradaxa® On Kidney Function Over Time Compared To Warfarin 9/2/2014
Sanofi Pasteur (SASY.PA) Touts Positive Trial Data For Fluzone High-Dose Vaccine 8/14/2014
Scientists Retract Narcolepsy Study Linked To GlaxoSmithKline (GSK) Flu Vaccine 8/11/2014
Study Claims Celgene (CELG) Drug Can Drive HIV Out Of Hiding 7/25/2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands 7/21/2014
Shire Reports Results From Two Head-To-Head Studies Comparing Vyvanse® With Concerta® In ADHD Study 7/18/2014
Merck & Co., Inc. (MRK)'s Gardasil HPV Vaccine Doesn't Increase Blood Clot Risk 7/9/2014
Roche (RHHBY) Finds "Serious Flaws" In Recent Study Doubting Tamiflu's Effectiveness 7/1/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression 6/26/2014
A 4-Week Hepatitis C Cure? Bristol-Myers Squibb Company (BMY) To Test Drugs With Gilead Sciences, Inc. (GILD)'s Sovaldi 6/23/2014
H. Lundbeck A/S (LUN.CO) Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Results Of A New Study Of Brintellix® (vortioxetine) vs. Escitalopram On Sexual Functioning In Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Shows That Brintellix® (Vortioxetine) Improves Cognitive Performance And Function In Adult Patients With Major Depression 6/16/2014
Hemispherx Biopharma (HEB) Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS) 6/16/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Boehringer Ingelheim Corporation Release: Antidote For Rapid Reversal Of Pradaxa® (Dabigatran Etexilate) Progresses Into Next Stage Of Clinical Investigation With Study In Patients 5/22/2014
GlaxoSmithKline (GSK) Touts Positive Incruse™-Ellipta®-Advair®-Diskus® Combo Data 5/20/2014
Biohit Release: Enrollment To Clinical Trials For Prevention Of Migraine-Type Headache 5/19/2014
Biohit Starts Two Clinical Trials With Acetium® Capsule For Prevention Of Migraine-Type Headache 4/29/2014
Head-To-Head Study Reveals Novartis AG (NVS) Lung Drug Not Inferior To GlaxoSmithKline (GSK)'s Seretide 4/28/2014
Saga Continues: Roche (RHHBY)'s Tamiflu No Better Than Tylenol At "Fighting Flu" 4/14/2014
FDA Grants Breakthrough Status Designation To Novartis AG (NVS)' Meningitis B Vaccine 4/8/2014
H. Lundbeck A/S (LUN.CO) Release: Treatment With Once-Monthly Abilify Maintena® (Aripiprazole) Significantly Reduces Hospitalisation Rates For Patients With Schizophrenia Compared With Daily Oral Antipsychotics 4/7/2014
Roche (RHHBY)-Backed Study Finds Tamiflu Saved Lives In Flu Pandemic 3/19/2014
uniQure And Chiesi Farmaceutici SpA Announce Six Year Follow-up Data from Glybera® Treated Patients 3/17/2014
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014
Baxter International, Inc. (BAX) Presents Data At EAHAD From Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience With ADVATE 2/27/2014
Roche (RHHBY) May Share Avastin Brain Cancer Data Amid Conflicting Results 2/21/2014
Ranbaxy Laboratories (RANBAXY.BO) Workers Fudged Test Results: FDA 1/28/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE® (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate 1/13/2014
German Watchdog Deals Setback To Bayer AG (BAYN.DE) Eye Drug Eylea 1/6/2014
AstraZeneca PLC (AZN)'s Arimidex Halves Breast Cancer Risk, Study Finds 12/12/2013
Lundbeck Inc. (LUN.CO) Release: New Study Showed Improvement In Cognitive Performance In Adult Patients Treated With Brintellix® (Vortioxetine) For Acute Episodes Of Major Depression 12/11/2013
Zealand Pharma  (ZEAL.CO) Informs That New Data Presented At The World Diabetes Congress Support Flexibility In Timing Of Administration For Lyxumia® 12/5/2013
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/2/2013
Boehringer Ingelheim Corporation Release: Pradaxa® (Dabigatran Etexilate) 150mg Bid Continues To Be The Only Oral Anticoagulant Which Showed Superior Ischaemic Stroke Reduction Vs. Warfarin In Its Pivotal Study RE-LY® 11/25/2013
Boehringer Ingelheim Corporation Planning Two New Global Clinical Trials For Pradaxa® (Dabigatran Etexilate) In Expanded Patient Populations 11/19/2013
First Human Data Show Promise Of Boehringer Ingelheim Corporation’s Specific Antidote For Immediate, Complete And Sustained Reversal Of Pradaxa®-Induced Anticoagulation 11/18/2013
EU Agency Questions AstraZeneca PLC (AZN) Over Heart Drug Trial 11/8/2013
Ibuprofen No Good in Treating Colds or Sore Throats, University of Southampton Study 11/5/2013
Roche (RHHBY)'s Avastin Boosts Survival in Advanced Ovarian Cancer 10/23/2013
Novo Nordisk A/S (NVO) Study Shows Tresiba Efficacy for Diabetes 9/26/2013
Data Show Sanofi (France) (SAN.PA)'s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially When Fasting Plasma Glucose Was Controlled 9/24/2013
Roche (RHHBY)'s Perjeta Works in Early-Stage Breast Cancer 9/11/2013
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study 9/3/2013
FDA Probes Brain Infection in Patient on Novartis AG (NVS)'s MS Drug 9/3/2013
Novartis AG (NVS)'s Afinitor® Fails Phase 3 Liver Cancer Trial 8/8/2013
Orexo AB: First Patient Dosed in New Study on Long-Term Adherence to Treatment of Opioid Dependence With Zubsolv® 8/7/2013
Deja Vu: Second Probe Finds Manipulated Trial Data for Novartis AG (NVS) Drug 8/5/2013
Celgene International Sárl (CELG) Release: Study of REVLIMID® (lenalidomide) in Patients with High-Risk Asymptomatic Smoldering Multiple Myeloma Published in The New England Journal of Medicine 8/1/2013
European Medicines Agency Approves SmPC Change to Baxter International, Inc. (BAX)’s ADVATE to Include Information on PK-Guided Dosing Study 7/22/2013
Roche (RHHBY)'s Avastin as Good as Novartis AG (NVS)'s Lucentis for AMD 7/19/2013
Boehringer Ingelheim Corporation Release: Benefits of Pradaxa® Maintained in Difficult to Treat Patients With Atrial Fibrillation and Symptomatic Heart Failure 7/16/2013
Novartis AG (NVS) Drug Study Data Manipulated: Kyoto Prefectrual University of Medicine 7/16/2013
Baxter International, Inc. (BAX) Presents ADVATE Data on Prophylaxis Management and Efficacy for Hemophilia A Patients 7/8/2013
Boehringer Ingelheim Corporation Release: New Long-Term Data Reinforce Safety Profile of Pradaxa® for Stroke Prevention in AF 6/17/2013
Celgene International Sárl (CELG) Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients With Rare Form of Blood Disease 6/17/2013
Novo Nordisk A/S (NVO) Release: Victoza® (Liraglutide [rDNA Origin] Injection) Safety Profile Further Supported at Scientific Workshop on Pancreatitis, Diabetes and Pancreatic Cancer 6/14/2013
AbbVie (ABBV) Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination With HUMIRA™ (adalimumab) for Rheumatoid Arthritis 6/13/2013
Bristol-Myers Squibb Company (BMY)'s Orencia Matches Abbott Laboratories (ABT)' Humira in Arthritis Study 6/12/2013
Merck & Co., Inc. (MRK) Joins Novo Nordisk A/S (NVO) to Reassure Safety of Diabetes Drugs 6/12/2013
Sanofi (France) (SAN.PA) Steps Up Diabetes Drive as Rivals Raise the Stakes 6/10/2013
Eisai Company, Ltd. (ESALY.PK) Confirms Therapeutic Effects of Lenvatinib in Patients With Melanoma in Strategic Collaboration With Quintiles, Inc. (Q) to Develop Eisai Anticancer Compounds 6/10/2013
New Bird Flu Found to be Resistant to Roche (RHHBY)'s Tamiflu 5/30/2013
Boehringer Ingelheim Corporation Release: New European Survey Highlights Ischaemic Stroke Protection as Treatment Priority for Patients With Atrial Fibrillation 5/28/2013
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO): Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1 5/21/2013
"Love Hormone" Promises Safer Births After Pfizer Inc. (PFE) Flop 5/21/2013
Teva Pharmaceutical Industries Limited (TEVA) Parkinson's Treatment Meets Study Goals 3/20/2013
German Cost Regulator Rejects Bayer AG (BAY.F) and Regeneron Pharmaceuticals, Inc. (REGN) Eye Drug 3/20/2013
EU Expands Use of Roche (RHHBY)'s Pegasys in Chronic Hepatitis C 3/18/2013
Ferring Pharmaceuticals Data Suggest Lower Risk of Cardiovascular Events or Deaths in Prostate Cancer Patients Treated With Degarelix Compared to LHRH Agonists 3/18/2013
AbbVie (ABBV) Seeks to Block Release of Clinical Trial Data 3/11/2013
Serious Side Effects Seen With Failed Merck & Co., Inc. (MRK) Niacin Drug 3/11/2013
Roche (RHHBY)'s Rituxan Cures Rare Skin-Blistering Disease in Study 3/8/2013
National Institute for Clinical Excellence (NICE) U-Turn on Novartis AG (NVS)'s Xolair for Asthma 3/7/2013
Boehringer Ingelheim Corporation Release: New Findings From Two Studies Support Substantial Benefit of Pradaxa® for Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism 2/21/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix 1/24/2013
Novartis AG (NVS) Says Afinitor Reduces Tumors in Rare Genetic Disease 1/11/2013
Merck & Co., Inc. (MRK)'s Tredaptive is Under Review by European Medicines Agency After Failed Trial 12/26/2012
Immune Response BioPharma Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS 12/13/2012
Novo Nordisk A/S (NVO) Bets on Turning Victoza Into Obesity Blockbuster 12/12/2012
Celgene International Sárl (CELG) Release: Analysis of Post-Progression Outcomes in MM-015 Study Presented at the 54th American Society of Hematology Annual Meeting 12/11/2012
Genentech (RHHBY)'s Perjeta Extends Life of Breast Cancer Patients by 34 Pct 12/11/2012
Celgene (CELG) Release: REVLIMID® and VIDAZA® Combination Therapy Achieves Nearly 30 Percent Complete Response in Untreated Elderly Patients With Acute Myeloid Leukemia 12/11/2012
Boehringer Ingelheim Corporation Release: Treatment With Pradaxa® Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin 12/10/2012
GlaxoSmithKline (GSK): We Conducted Paxil Clinical Trial Program Appropriately 12/7/2012
AstraZeneca PLC (AZN) Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2 12/5/2012
Eli Lilly and Company (LLY)'s ED Drug, Cialis, Shows Promise in Rare Muscle Disease 11/30/2012
Digoxin for Atrial Fibrillation Questioned After Deaths, Study Published in the European Heart Journal 11/28/2012
Novo Nordisk A/S (NVO) Says New Data Show Victoza Advantage 11/27/2012
Roche (RHHBY)'s Avastin Shows Mixed Results in Glioblastoma 11/23/2012
Gilead Sciences, Inc. (GILD)'s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients 11/15/2012
Gilead Sciences, Inc. (GILD)'s Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naive HIV Patients 11/15/2012
Boehringer Ingelheim Corporation Release: Recruitment Complete for Trajenta ® (linagliptin) Cardiovascular Outcome Study in Patients With Type 2 Diabetes 11/8/2012
Boehringer Ingelheim Corporation Release: RELY-ABLE®: Unprecedented Long-Term Data Support Safety Profile and Sustained Efficacy of Pradaxa® for Stroke Prevention in AF 11/8/2012
Boehringer Ingelheim Corporation Release: Safety and Efficacy of Pradaxa® (dabigatran etexilate) Reconfirmed in Clinical Setting for VTE Prevention After Total Knee or Hip Replacement 11/6/2012
Novartis AG (NVS) Drug Works to Treat Rare Cushing's Disease 11/6/2012
Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation 11/5/2012
GlaxoSmithKline (GSK), Roche (RHHBY) Drugs Help Treat Breast Cancer in Brain 11/2/2012
Wealth of Worldwide Evidence on Boehringer Ingelheim GmbH's Pradaxa® Including First Clinical Data on Long-Term Efficacy and Safety of a Novel Oral Anticoagulant to be Presented at American Heart Association Scientific Sessions 10/31/2012
Novartis AG (NVS) Cannibalizes Gleevec to Boost New Cancer Drug 10/29/2012
Sleep Tight: GlaxoSmithKline (GSK) Vaccine Not Linked To Narcolepsy 10/19/2012
Eisai Company, Ltd. (ESALY.PK)'s Epilepsy Drug Helps Obese Patients Lose Weight 10/17/2012
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Makes Progress With MS Drugs 10/15/2012
Novartis AG (NVS)'s Gilenya Cuts Early Relapse, Brain Loss in MS Patients 10/12/2012
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People With Relapsing Forms of MS 10/11/2012
Sanofi (France) (SAN.PA) Says Zaltrap Cancer Drug Study Positive 10/9/2012
Sanofi (France) (SAN.PA) Flags Positive Study on Lantus Insulin 10/5/2012
Cancer Trials Show One Year on Roche (RHHBY)'s Herceptin is Best 10/1/2012
Celgene (CELG)'s Abraxane is Talk of Cancer Meeting 10/1/2012
New Janssen Pharmaceutica N.V. Data Demonstrate STELARA® (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients With Moderate to Severe Plaque Psoriasis 9/28/2012
Boehringer Ingelheim GmbH Release: Asian Populations With Atrial Fibrillation (AF) Benefit From Better Stroke Prevention With Pradaxa® (dabigatran etexilate) Compared to Warfarin 9/12/2012
New Data Confirms Safety of Novartis AG (NVS)'s Eye Drug Lucentis 9/5/2012
Novartis AG (NVS) Smoker's Cough Treatment Beats GlaxoSmithKline (GSK)'s Advair in Trial 8/29/2012
Bayer AG (BAY.F) Says Blood Thinner Cuts Risk of Repeat Heart Attack 8/29/2012
The Medicines Company (MDCO) Release: Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin 8/28/2012
AstraZeneca PLC (AZN) Release: New European Society of Cardiology Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients With ST-Elevation 8/28/2012
Daiichi Sankyo, Inc. (4568.t), Eli Lilly and Company (LLY) Say Heart Drug Effient Fails to Meet Goal in a Phase III Trial 8/27/2012
Boehringer Ingelheim Corporation Release: Cost Effectiveness and Clinical Efficacy of Pradaxa® (Dabigatran Etexilate) Versus Rivaroxaban Analysed 8/24/2012
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin 8/13/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study 8/13/2012
Roche (RHHBY) Says Avastin Slows Brain Cancer Tumor Growth 8/10/2012
Bristol-Myers Squibb Company (BMY) & AstraZeneca PLC (AZN) Release: Pooled Analysis Showed Onglyza® (saxagliptin) Provided Improvements in Key Measures of Blood Sugar Control in Adults With Type 2 Diabetes at High Risk for CV Disease 7/30/2012
Roche (RHHBY)'s Lucentis Works to Treat Vision Loss from Diabetes 7/25/2012
AstraZeneca PLC (AZN) Starts New Study of Heart Drug Versus Rival 7/18/2012
GlaxoSmithKline (GSK), Shionogi & Co., Ltd. Say HIV Drug Beats Gilead Sciences, Inc. (GILD) Atripla in Test 7/11/2012
Merck KGaA (MKGAF.PK) Says Erbitux Fails in Stomach Cancer Trial 7/6/2012
Orexo AB Takes Large Step Forward on the Road to Improve Treatment for People Dependent on Opioid Pain Killers 7/2/2012
Boehringer Ingelheim Corporation Release: No Significant Difference in the Risk of Acute Coronary Syndrome (including Myocardial Infarction) Seen With Pradaxa®(dabigatran etexilate) Compared to Enoxaparin for VTE Prevention After Orthopaedic Surgery 6/25/2012
Genentech (RHHBY) Says Perjeta Combination Increased Survival in Breast Cancer Patients 6/22/2012
FDA Staff Question Value of Sanofi (France) (SAN.PA) Blood Clot Drug 6/18/2012
Sanofi (France) (SAN.PA) Announces Results of ORIGIN, the World's Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes 6/15/2012
GlaxoSmithKline (GSK)'s Avandia and University of Nottingham's Actos are Linked to Vision Problems 6/13/2012
New Epidemiological Data Provide Additional Safety Evidence for Sanofi (France) (SAN.PA)'s Lantus(R) 6/12/2012
Alkermes plc (ALKS) Release: INVEGA® SUSTENNA® Three-Month Formulation of Paliperidone Palmitate Enters Phase 3 Clinical Program for Schizophrenia 6/12/2012
Sanofi (France) (SAN.PA)'s Lantus Shows No Cancer, Heart Risks: Study 6/12/2012
Novo Nordisk A/S (NVO) Says Victoza Superior to Amylin Pharmaceuticals, Inc. (AMLN) Rival 6/12/2012
Sanofi (France) (SAN.PA)'s Lantus Cut Blood Sugar More Than Merck & Co., Inc. (MRK)'s Januvia 6/11/2012
Data From Follow-Up Study of Vertex Pharmaceuticals Incorporated (VRTX)' KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People With Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D) 6/8/2012
Roche (RHHBY)'s Actemra Beats Abbott Laboratories (ABT) Drug in RA Trial 6/7/2012
European Medicines Evaluation Agency Confirms Boehringer Ingelheim Corporation's Pradaxa Benefits, But Wants Clearer Guidance 5/25/2012
Roche (RHHBY)'s Genentech (RHHBY) to Take Part in First-ever Alzheimer's Prevention Trial 5/21/2012
Merck KGaA (MKGAF.PK)'s Erbitux Fails in Colon Cancer Study 5/9/2012
Roche (RHHBY)'s Avastin and Novartis AG (NVS)'s Lucentis Equal for Treating Wet AMD - National Institutes of Health (NIH) Study 5/2/2012
New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) (BIIB) & Biogen Idec, Inc. (Massachusetts) (BIIB) Commitment to Improving Outcomes in Multiple Sclerosis 4/27/2012
Johnson & Johnson (JNJ) Alzheimer's Med Cut Chemical Tied to Brain Tangles 4/3/2012
Servier's Protelos Effective Against Weak Bones 3/26/2012
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Complete Registrational Program for Relovair; Reports Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD 3/23/2012